The adjuvant treatment revolution for high-risk melanoma patients
- PMID: 31445219
- DOI: 10.1016/j.semcancer.2019.08.024
The adjuvant treatment revolution for high-risk melanoma patients
Abstract
The past 5 years have witnessed the results of many practice-changing studies that have dramatically improved the landscape of adjuvant therapy in patients with resected, high-risk melanoma. After a 20-year era of adjuvant interferon, the anti-CTLA-4 and anti-PD-1 immune-checkpoint inhibitors, and MAPK-directed targeted therapy brought a revolution into the adjuvant treatment of melanoma. These results came along with the practice-changing results of two large multicenter studies showing no benefit in terms of overall survival for completion lymph node dissection after positive sentinel node biopsy. In this review, we summarized the current state of the art of the adjuvant treatment of high-risk melanoma, with a view on future perspectives.
Keywords: Adjuvant; Immunotherapy; Melanoma; Neoadjuvant; Targeted therapy.
Copyright © 2019. Published by Elsevier Ltd.
Similar articles
-
Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.Recent Results Cancer Res. 2000;157:178-89. doi: 10.1007/978-3-642-57151-0_15. Recent Results Cancer Res. 2000. PMID: 10857171 Review.
-
Neoadjuvant Immunotherapy for Locally Advanced Melanoma.Curr Treat Options Oncol. 2020 Feb 5;21(2):10. doi: 10.1007/s11864-020-0700-z. Curr Treat Options Oncol. 2020. PMID: 32025932 Review.
-
Adjuvant Treatment of Melanoma: Recent Developments and Future Perspectives.Am J Clin Dermatol. 2019 Dec;20(6):817-827. doi: 10.1007/s40257-019-00456-4. Am J Clin Dermatol. 2019. PMID: 31177507 Review.
-
Uncertainties in the management of melanoma nodal metastasis.Eur J Surg Oncol. 2015 Jul;41(7):811-3. doi: 10.1016/j.ejso.2015.04.011. Epub 2015 Apr 30. Eur J Surg Oncol. 2015. PMID: 25980747 No abstract available.
-
The impact of the immunotherapy revolution on lymph nodal surgery.Bull Cancer. 2020 Jun;107(6):640-641. doi: 10.1016/j.bulcan.2019.05.013. Epub 2019 Oct 11. Bull Cancer. 2020. PMID: 31610910 No abstract available.
Cited by
-
Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1/2-mediated reactivation of MEK/ERK/MYC signaling.Nat Commun. 2020 Oct 29;11(1):5463. doi: 10.1038/s41467-020-19075-3. Nat Commun. 2020. PMID: 33122628 Free PMC article.
-
The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape.Front Mol Biosci. 2020 Jun 30;7:113. doi: 10.3389/fmolb.2020.00113. eCollection 2020. Front Mol Biosci. 2020. PMID: 32695793 Free PMC article. Review.
-
Cinobufagin Induces Cell Cycle Arrest at the G2/M Phase and Promotes Apoptosis in Malignant Melanoma Cells.Front Oncol. 2019 Sep 4;9:853. doi: 10.3389/fonc.2019.00853. eCollection 2019. Front Oncol. 2019. PMID: 31552178 Free PMC article.
-
AP-2α-Mediated Activation of E2F and EZH2 Drives Melanoma Metastasis.Cancer Res. 2021 Sep 1;81(17):4455-4470. doi: 10.1158/0008-5472.CAN-21-0772. Epub 2021 Jul 1. Cancer Res. 2021. PMID: 34210752 Free PMC article.
-
Effective pressure and treatment duration of high hydrostatic pressure to prepare melanoma vaccines.Oncol Lett. 2020 Aug;20(2):1135-1142. doi: 10.3892/ol.2020.11657. Epub 2020 May 21. Oncol Lett. 2020. PMID: 32724353 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
